personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
Welcome to the June issue! This month, our cover feature delves into the green rush of cannabinoids, and pharma’s fascination with creating medicines from the cannabis plant. In My View sees experts discuss explosive chemical reactions, extended ANDA approval times, and the upcoming serialization deadlines. We also investigate the story behind the world’s first JAK inhibitor for rheumatoid arthritis, how the trends in small-molecule drugs are affecting outsourcing, the importance of manufacturing strategies in bioprocessing, and what the UK’s Brexit decision means for pharmacovigilance. Plus, we sit down with Elisa Cascade, President of Data Solutions at DrugDev.